Company intelligence / Profile preview

Deciphera Pharmaceuticals

Waltham, Massachusetts, United Statesdeciphera.com ↗

Ownership: Public · DCPH
Employees: ~350
Development stage: Commercial

Overview

Deciphera has received FDA approval for ROMVIMZA™ (vimseltinib) for the treatment of Tenosynovial Giant Cell Tumor (TGCT). Their MOTION Phase 3 study met its primary endpoint with an Objective Response Rate of 40% compared to 0% for placebo. They also have QINLOCK® approved for fourth-line GIST treatment in multiple countries.

Therapeutic areas: GastroenterologyOncologyImmunologyHematology
Modalities: Small moleculesKinase inhibitors
Industry: Biotech

Drug pipeline

10 assets

vimseltinib

Approved

9 more assets in the full pipeline.

Request access →

Financials

Market cap: $2.2B
Total revenue: $45M
Enterprise value: $2B

Beyond the preview

Go deeper on Deciphera Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Deciphera Pharmaceuticals.

Explore the full profile